Fibrinolytic activity in blood and cerebrospinal fluid in subarachnoid hemorrhage from ruptured intracranial saccular aneurysm before and during EACA treatment
- PMID: 624294
- DOI: 10.1159/000114920
Fibrinolytic activity in blood and cerebrospinal fluid in subarachnoid hemorrhage from ruptured intracranial saccular aneurysm before and during EACA treatment
Abstract
10 patients suffering from intracranial aneurysm causing subarachnoid hemorrhage (SAH) have been treated during the acute pre-and postoperatory phase with omega-aminocaproic acid. The blood and the cerebrospinal fluid of the treated patients have been analyzed in order to study fibrin(ogen) degradation products (FDP) and fibrinolytic activity (FA). The results so obtained show only an alteration of local fibrinolytic processes either inside or around the aneurysmatic clot: there were no alterations of the systemic FA. Furthermore, monitoring of FDP and FA was a very useful tool in those patients who took advantage of the treatment with omega-aminocaproic acid which protected them from rebleeding.
Similar articles
-
Quantitative determination of plasma fibrinolytic activity in patients with ruptured intracranial aneurysms who are receiving epsilon-aminocaproic acid: relationship of possible complications of therapy to the degree of fibrinolytic inhibition.Neurosurgery. 1984 Jan;14(1):57-63. doi: 10.1227/00006123-198401000-00012. Neurosurgery. 1984. PMID: 6537999
-
Monitoring of antifibrinolytic therapy following subarachnoid hemorrhage. The importance of CSF fibrin/fibrinogen degradation products.J Neurosurg. 1983 May;58(5):699-707. doi: 10.3171/jns.1983.58.5.0699. J Neurosurg. 1983. PMID: 6834119
-
Epsilon-aminocaproic acid and recurrent subarachnoid hemorrhage: a clinical trial.J Neurosurg. 1980 Jul;53(1):28-31. doi: 10.3171/jns.1980.53.1.0028. J Neurosurg. 1980. PMID: 7411206
-
Antifibrinolytic therapy in subarachnoid hemorrhage caused by ruptured intracranial aneurysm.Neurology. 1981 Mar;31(3):316-22. doi: 10.1212/wnl.31.3.316. Neurology. 1981. PMID: 7010208 Review.
-
Monitoring of fibrin and fibrinogen degradation products (FDP) in the cerebrospinal fluid of patients with subarachnoid haemorrhage due to ruptured aneurysm. Report of 55 cases.J Neurosurg Sci. 1994 Jun;38(2):77-86. J Neurosurg Sci. 1994. PMID: 7891197 Review.
Cited by
-
Impact of time to start of tranexamic acid treatment on rebleed risk and outcome in aneurysmal subarachnoid hemorrhage.Eur Stroke J. 2024 Sep;9(3):658-666. doi: 10.1177/23969873241246591. Epub 2024 Apr 12. Eur Stroke J. 2024. PMID: 38606724 Free PMC article. Clinical Trial.
-
Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study.Acta Neurochir (Wien). 1990;102(1-2):1-10. doi: 10.1007/BF01402177. Acta Neurochir (Wien). 1990. PMID: 2407050 Clinical Trial.
-
Coagulation and fibrinolysis in blood and cerebrospinal fluid after aneurysmal subarachnoid haemorrhage: effect of tranexamic acid (AMCA).Acta Neurochir (Wien). 1981;56(1-2):25-38. doi: 10.1007/BF01400969. Acta Neurochir (Wien). 1981. PMID: 7195642 Clinical Trial.
-
Letter to the editors of acta neurochirurgica. Management of patients with subarachnoid haemorrhage with tranexamic acid.Acta Neurochir (Wien). 1980;54(1-2):127-31. doi: 10.1007/BF01401951. Acta Neurochir (Wien). 1980. PMID: 7435290 No abstract available.
-
Prediction of cerebral vasospasm value of fibrinogen degradation products (FDP) in the cerebro-spinal fluid (CSF) for prediction of vasospasm following subarachnoid haemorrhage due to a ruptured aneurysm.Acta Neurochir (Wien). 1984;73(1-2):25-33. doi: 10.1007/BF01401781. Acta Neurochir (Wien). 1984. PMID: 6496196
MeSH terms
Substances
LinkOut - more resources
Full Text Sources